Applications are invited from Brilliant young candidates for the position of Assistant and Associate Professors at the Centre for Data Science  (Cloud Computing, Financial and Business Data Analytics ,Big Data and Internet of Things).Centre for Interdisciplinary Sciences ( Paint and Coating Technology ,Additive Manufacturing and 3D Printing ,Photovoltaic system ,Fuel Cell and Battery Technology, Wind and Bio Energy ).Centre for Health Science (Bio Medical Instrumentation , Medical Image Processing, Molecular Human Genetics (Population Genetics).Eligibility as per UGC norms.Apply at  || Best Private Post-graduate Research Institute in Eastern Region of India || JISIASR has bagged the TV9 Bangla Award 2022 under the category of EXCELLENCE FOR RESEARCH & ADVANCED STUDIES


Prabir Ckakraborty

Adjunct Professor (Honorary)

Principal Program Manager
Calico Life Sciences, San Francisco, CA, USA

Dr. Prabir Chakraborty is a Senior Management Professional working in the Project Management department directing First-in-Class Drug Development programs at Google’s Calico Labs. Before joining Google, Dr. Chakraborty worked in a senior management role for Research Strategic Operations at Gilead Sciences (CA, USA) where he planned and executed various CAR-T pipeline development in both solid and heme tumors. Dr. Chakraborty has been a seasoned research and corporate strategists in the biotechnology industry. He has patents pertaining to immunooncology assets that have paved way to clinical trials.

Dr. Chakraborty came to Gilead Sciences from Arch Oncology, where he led immuno-oncology programs targeting CD47 in both solid and hematological cancers. He was involved in managing IND enabling studies, translational research and new pipeline development. Prior to that, Dr. Chakraborty was a Research Assistant Professor at Stephenson Cancer Center in Oklahoma focusing on ovarian and pancreatic cancer research. Dr. Chakraborty received his PhD from Jadavpur University, targeting signaling pathways as a combinatorial therapy for chronic myelogenous leukemia and conducted his post-doctoral research at the University of Florida on novel GPCR targets in prostate cancer.